Effectiveness of pharmacist-managed oncology ambulatory care for patients with non-small cell lung cancer in Taiwan.

Publisher: Food and Drug Administration, Taiwan Country of Publication: China (Republic : 1949- ) NLM ID: 101630927 Publication Model: Print Cited Medium: Internet ISSN: 2224-6614 (Electronic) NLM ISO Abbreviation: J Food Drug Anal Subsets: MEDLINE

Publication: [Taipei, Taiwan] : Food and Drug Administration, Taiwan
Original Publication: [Taipei City, Taiwan, R.O.C.] : Elsevier, 2013-

Carcinoma, Non-Small-Cell Lung*/drug therapy ; Pharmacists* ; Lung Neoplasms*/drug therapy ; Ambulatory Care*; Humans ; Male ; Female ; Taiwan ; Aged ; Retrospective Studies ; Middle Aged ; Antineoplastic Agents/therapeutic use ; Aged, 80 and over

Non-small cell lung cancer (NSCLC) is commonly treated with tyrosine kinase inhibitors (TKIs). However, adverse events from such treatment can lead to treatment discontinuation and additional medical expenditures. Ambulatory care from oncology pharmacists in patient education and symptom management can benefit patients with NSCLC. In this study, we evaluated the effectiveness of an oncology pharmacy service at a medical center in Taiwan. We retrospectively enrolled 137 patients with NSCLC who initiated treatment with afatinib, gefitinib, or erlotinib between January 2017 and December 2021; 40 of them utilized the oncology pharmacy service (intervention group), and the remaining 97 did not (nonintervention group). To determine the effectiveness of the oncology pharmacy service, we analyzed the following outcomes: adverse event rates, number of hospital visits (unexpected outpatient department visits, emergency department visits, and hospitalization), and medical expenditure. The intervention group had significantly more skin-related adverse events (acneiform rash: 75% vs. 49%; mucositis: 40% vs. 21%; dermatitis: 30% vs. 9%; and paronychia: 85% vs. 28%) but significantly fewer monthly emergency department visits (0.04 vs. 0.17) and unexpected outpatient department visits (0.15 vs. 0.34). The intervention group also had significantly lower expenditure for emergency department visits (NT$166.4 vs. NT$734.8) and nonsignificantly lower expenditure for outpatient department visits. Our findings indicate the value of pharmacist-managed ambulatory oncology care. Although this service did not reduce the incidence rates of adverse events, it reduced the number of unplanned outpatient and emergency department visits and reduced the emergency department expenditure of patients with NSCLC receiving TKIs.

J Oncol Pract. 2018 Jun;14(6):e324-e334. (PMID: 29799768)
J Oncol Pharm Pract. 2016 Dec;22(6):777-783. (PMID: 26493871)
Asia Pac J Clin Oncol. 2016 Sep;12(3):e367-74. (PMID: 25227909)
Expert Opin Drug Saf. 2020 May;19(5):589-599. (PMID: 32267188)
Lancet Oncol. 2011 Aug;12(8):735-42. (PMID: 21783417)
Support Care Cancer. 1995 May;3(3):183-9. (PMID: 7655779)
J Eval Clin Pract. 2012 Aug;18(4):753-60. (PMID: 21414113)
J Natl Compr Canc Netw. 2022 May;20(5):497-530. (PMID: 35545176)
J Oncol Pract. 2019 Apr;15(4):e346-e355. (PMID: 30860937)
Lancet Oncol. 2014 Feb;15(2):213-22. (PMID: 24439929)
J Cancer Educ. 2022 Oct;37(5):1553-1561. (PMID: 35867307)
Int J Clin Pharm. 2016 Apr;38(2):280-8. (PMID: 26715547)
Thorac Cancer. 2023 Feb;14(4):348-356. (PMID: 36525509)
J Pharm Health Care Sci. 2022 Mar 2;8(1):8. (PMID: 35236407)
Crit Rev Oncol Hematol. 2016 May;101:158-68. (PMID: 26995080)
J Thorac Oncol. 2019 Jan;14(1):99-106. (PMID: 30240852)
N Engl J Med. 2010 Jun 24;362(25):2380-8. (PMID: 20573926)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Oncol Rep. 2017 Mar;37(3):1347-1358. (PMID: 28184913)
Support Care Cancer. 2013 May;21(5):1287-93. (PMID: 23179492)
J Natl Compr Canc Netw. 2016 Mar;14(3):279-85. (PMID: 26957614)
Support Care Cancer. 2012 Nov;20(11):2669-77. (PMID: 22298194)
J Oncol Pharm Pract. 2017 Sep;23(6):413-421. (PMID: 27328684)
J Natl Cancer Inst. 2017 Jun 1;109(6):. (PMID: 28376144)
J Clin Pharm Ther. 2017 Aug;42(4):414-424. (PMID: 28556392)
Cancer. 2021 Aug 15;127(16):3029-3030. (PMID: 34086348)
Ann Oncol. 2018 Jan 1;29(suppl_1):i3-i9. (PMID: 29462253)

0 (Antineoplastic Agents)

Date Created: 20250103 Date Completed: 20250103 Latest Revision: 20250106

20250114

PMC11698597

10.38212/2224-6614.3528

39752872